Evidence map›Paper›PMID 41581871›Full record

ArticleThe Journal of biological chemistry2026

Cytosolic nucleic acid sensing triggers type I interferon activation via the Hippo kinase LATS1.

Tim Nass, Anna D Reichardt, Saba R Aliyari, Emily Tom, Gage LeMunyan, Michelle S Parvatiyar, Genhong Cheng, Kislay Parvatiyar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tim NassDepartment of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Anna D ReichardtDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA; Medical Scientist Training Program, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Saba R AliyariDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA.
Emily TomDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA.
Gage LeMunyanDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA.
Michelle S ParvatiyarDepartment of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, Florida, USA.
Genhong ChengDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA.
Kislay ParvatiyarDepartment of Health, Nutrition, and Food Sciences, Florida State University, Tallahassee, Florida, USA. Electronic address: kparvatiyar@fsu.edu.

Funding

Pilot Projects ProgramP30GM145498 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI S MICHAL JAZWINSKI · 2022 to 2026
$8.6M
NIGMS NIH HHS P30 GM145498
6 · The paper itself

Abstract

Innate immune detection of viral genomes via nucleic acid-sensing pattern recognition receptors in the cytosolic compartment triggers the production of type I interferons (IFN-I) to coordinate a cellular antiviral state to limit viral replication and spread. While IFN-I induction is controlled primarily by the IRF3 transcription factor, which undergoes phosphorylation-dependent activation via the virus-activated kinase, TBK1, the mechanisms underlying how TBK1 signaling is achieved remain incompletely understood. Here, we report that viral infection or cytosolic delivery of nucleic acids elicits the activation of a primordial Hippo signaling pathway that is known to control organ size and tissue homeostasis. We identify the Hippo core component, LATS1 kinase to necessitate TBK1 dependent signaling as cells treated with a pharmacological inhibitor of LATS1 or cells from Lats1

Indexed as

CytosolInterferon Type INucleic AcidsProtein Serine-Threonine KinasesAnimalsHumansInterferon Regulatory Factor-3MiceMice, KnockoutSignal TransductionInterferon Regulatory Factor-3Interferon Type ILATS1 protein, humanLats1 protein, mouseNucleic AcidsProtein Serine-Threonine KinasesTbk1 protein, mouseHippo signalinginnate antiviral signalinginterferon regulatory factor 3 (IRF3)large tumor suppressor 1 (LATS1)pattern recognition receptors (PRRs)TANK binding kinase 1 (TBK1)type I interferon (IFN-I)

Identifiers

PMID41581871
PMCPMC12927312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.